Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 35 Gatehouse Drive, Building D, Floor 3 WALTHAM MA 02451 |
Tel: | N/A |
Website: | https://syndax.com |
IR: | See website |
Key People | ||
Neil Gallagher President, Head of Research and Development | Michael A. Metzger Chief Executive Officer, Director | Keith A. Goldan Chief Financial Officer |
Luke J. Albrecht General Counsel, Secretary | Steven Closter Chief Commercial Officer | Catherine Madigan Chief Medical Officer |
Business Overview |
Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing pipeline of cancer therapies. Its product candidates include revumenib, and axatilimab. It is developing revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged also known as mixed lineage leukemia rearranged, acute leukemias including acute lymphoblastic leukemia and acute myeloid leukemia (AML), and necleophosmin 1, also known as NPM1, mutant A. It is also exploring the use of revumenib as a treatment in solid tumors, specifically its activity in metastatic colorectal cancer. It is also developing axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 receptor (CSF-1R) in chronic graft-versus-host disease (cGVHD), as well as idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. |
Financial Overview |
For the fiscal year ended 31 December 2023, Syndax Pharmaceuticals Inc revenues was not reported. Net loss increased 40% to $209.4M. Higher net loss reflects Research and development increase of 32% to $148.9M (expense), General and administrative increase from $23.3M to $50.1M (expense), Stock-based Compensation in R&D increase from $6M to $14.1M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$2.46 to -$2.98. |
Employees: | 112 as of Feb 19, 2024 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $1,189M as of Dec 31, 2023 |
Annual revenue (TTM): | $0.00M as of Dec 31, 2023 |
EBITDA (TTM): | -$229.94M as of Dec 31, 2023 |
Net annual income (TTM): | -$209.36M as of Dec 31, 2023 |
Free cash flow (TTM): | -$160.60M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 84,979,686 as of Mar 20, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |